drugset / Trial / NCT07078500
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2
Recruiting
48 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabDongyang People's Hospital · collabFirst People's Hospital of Hangzhou · collabHuzhou Central Hospital · collabNingbo People's Hospital · collabSecond Affiliated Hospital of Wenzhou Medical University · collabShaoxing Central Hospital · collabShaoxing People's Hospital · collabTaizhou First People's Hospital · collabTaizhou Hospital · collabThe Central Hospital of Lishui City · collabThe People's Hospital of Quzhou · collabThe Second Affiliated Hospital of Jiaxing University · collabYuyao People's Hospital · collabZhejiang Cancer Hospital · collabZhuji People's Hospital of Zhejiang Province · collab
NaSingle-groupOpen-labelTreatment
Summary
Assess the preliminary efficacy and safety of orelabrutinib in combination with the Pola-R-CHP regimen for the treatment of treatment-naive Non-GCB diffuse large B-cell lymphoma.
Timeline
- Start
- 2025-05-05
- Primary completion
- 2026-10-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orelabrutinib | Small molecule | — | — |